As the saying goes, there’s an app for that. And inflammatory bowel disease, or IBD, is no exception. IBD is an umbrella term for chronic inflammation-related conditions affecting the digestive system ...
This activity is supported by educational grants from AbbVie Inc.; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
AbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel disease (IBD) candidate.
Not only can the symptoms of IBD take a toll on a person’s physical health, but they can also cause some people embarrassment, which may cause them to withdraw from their family and friends. That’s ...
LOS ANGELES--(BUSINESS WIRE)--Investor’s Business Daily (IBD), a digital media company that provides authoritative stock market analysis, investing education and research tools, today announced that ...
Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. The program is the product of Omass’ ...
In patients with inflammatory bowel disease (IBD), treatment with GLP-1 receptor agonists is not associated with an increased incidence of gastrointestinal (GI) adverse events over 12 months.
A Teva Pharmaceuticals drug being developed in partnership with Sanofi to hit a promising but competitive target for inflammation now has positive data from a clinical test in the two most common ...
Consumers want financial companies they can trust. Is your bank, broker or insurer on this most-trusted list? Check out our 2025 list and find out more about why building and keeping customer trust is ...
Champions Ka Tashan will celebrate Makar Sankranti with challenges presented on kites. Malaika Arora and Geeta Kapur lead the ...
The ruling Congress in Telangana on Wednesday announced V Naveen Yadav as its candidate for the November 11 bypoll to Jubilee ...